Loading
Array BioPharma, of Boulder, Colorado, developed encorafenib and binimetinib, two pills taken together for melanoma with a BRAF mutation. Pfizer bought the company in 2019.
Array BioPharma Inc. (formerly Nasdaq: ARRY) was a commercial-stage company in Boulder, Colorado, that discovered and developed targeted small-molecule medicines. At the time of its sale its main products were BRAFTOVI (encorafenib) and MEKTOVI (binimetinib), approved together for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation and being tested in more than 30 trials, including the phase 3 BEACON trial in BRAF-mutant metastatic colorectal cancer. Pfizer agreed on 17 June 2019 to buy Array for USD 48 per share in cash, a total enterprise value of about USD 11.4 billion, through a tender offer, and the merger was completed on 30 July 2019.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · Pfizer's announcement of 17 June 2019, filed as exhibit 99.1 to Array's 8-K: USD 48 per share in cash, total enterprise value of approximately USD 11.4 billion | 2019 | $11.4B | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2019-06-17 | Array BioPharma to Pfizer (incl. Seagen) Encorafenib (Braftovi) and binimetinib (Mektovi) | Acquisition | not disclosed | $11.4bn | source |
Encorafenib is a BRAF inhibitor that, with cetuximab and chemotherapy, became first-line standard for BRAF-mutant colorectal cancer in 2026.
Binimetinib is the MEK inhibitor partnered with encorafenib; blocking the next step in the same relay stops the tumour rerouting around the BRAF block.
Shares Binimetinib, Encorafenib, Melanoma, Small-molecule kinase inhibitors.
Shares Encorafenib, BRAF, Melanoma, Colorectal cancer.
Shares Binimetinib, Encorafenib, Pfizer (incl. Seagen), Melanoma.
Shares Binimetinib, Encorafenib, Small-molecule kinase inhibitors.
Shares Encorafenib, Pfizer (incl. Seagen), Small-molecule kinase inhibitors, Colorectal cancer.
Shares MEK1/2, Small-molecule kinase inhibitors.
Shares Binimetinib, Encorafenib, BRAF, Pfizer (incl. Seagen).
Shares MEK1/2, BRAF, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/